Home › Funds › SAMLYN CAPITAL, LLC › ELVN
SAMLYN CAPITAL, LLC position in ELVN
ENLIVEN THERAPEUTICS INC · Health Care
SAMLYN CAPITAL, LLC reported holding 936,167 shares of ELVN (ENLIVEN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$42.9M, representing 0.72% of its reported portfolio and ranking #41 among its reported holdings. SAMLYN CAPITAL, LLC has disclosed ELVN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How SAMLYN CAPITAL, LLC's ELVN position evolved
SAMLYN CAPITAL, LLC first disclosed a stake in ELVN in Q2 2026 at 912,637 shares (US$46.3M). Across 2 filings, SAMLYN CAPITAL, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 936,167 shares valued at US$42.9M — an increase of 23,530 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 912.64K | $46.32M | New |
| Q3 2026 | 936.17K | $42.91M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ELVN and 13F data
ELVN (ENLIVEN THERAPEUTICS INC) is a Health Care company. 61 other funds we track also report a position in ELVN — the largest reported positions include ORBIMED ADVISORS LLC (US$343.9M), Polar Capital Holdings Plc (US$294.5M), Vestal Point Capital, LP (US$203.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ELVN
- ORBIMED ADVISORS LLC 6.78M sh · $343.91M · Q2 2026
- Polar Capital Holdings Plc 6.43M sh · $294.53M · Q3 2026
- Vestal Point Capital, LP 4.00M sh · $203.00M · Q2 2026
- Commodore Capital LP 3.27M sh · $166.21M · Q2 2026
- Fairmount Funds Management LLC 1.86M sh · $94.17M · Q2 2026
- Bellevue Group AG 1.49M sh · $75.62M · Q2 2026
- First Light Asset Management, LLC 1.36M sh · $69.06M · Q2 2026
- Siren, L.L.C. 1.48M sh · $67.62M · Q3 2026
- Novo Holdings A/S 1.00M sh · $50.75M · Q2 2026
- Logos Global Management LP 1.08M sh · $49.51M · Q3 2026
- BAKER BROS. ADVISORS LP 905.19K sh · $45.94M · Q2 2026
- First Turn Management, LLC 958.70K sh · $43.95M · Q3 2026
More on SAMLYN CAPITAL, LLC
FAQ
How long has SAMLYN CAPITAL, LLC held ELVN?
SAMLYN CAPITAL, LLC has disclosed ELVN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is SAMLYN CAPITAL, LLC's current position in ELVN?
As of Q3 2026, SAMLYN CAPITAL, LLC holds 936.17K shares of ELVN (ENLIVEN THERAPEUTICS INC), valued at $42.91M, representing 0.72% of its reported portfolio and ranking #41.
Has SAMLYN CAPITAL, LLC been buying or selling ELVN?
In the latest 13F filing (Q3 2026), SAMLYN CAPITAL, LLC increased its position in ELVN.
Which other funds hold ELVN?
Other major institutional holders of ELVN include ORBIMED ADVISORS LLC, Polar Capital Holdings Plc, Vestal Point Capital, LP, among 61 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.